| 000 | 01080 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250517210505.0 | ||
| 264 | 0 | _c20181024 | |
| 008 | 201810s 0 0 eng d | ||
| 022 | _a1742-4690 | ||
| 024 | 7 |
_a10.1186/s12977-018-0408-3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEakle, Robyn | |
| 245 | 0 | 0 |
_aPre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: Can it change the game? _h[electronic resource] |
| 260 |
_bRetrovirology _cApr 2018 |
||
| 300 |
_a29 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAnti-HIV Agents _xtherapeutic use |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aGuideline Adherence |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 | _aHIV-1 |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aOutcome Assessment, Health Care |
| 650 | 0 | 4 |
_aPre-Exposure Prophylaxis _xmethods |
| 700 | 1 | _aVenter, Francois | |
| 700 | 1 | _aRees, Helen | |
| 773 | 0 |
_tRetrovirology _gvol. 15 _gno. 1 _gp. 29 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s12977-018-0408-3 _zAvailable from publisher's website |
| 999 |
_c28242666 _d28242666 |
||